A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Deciphera Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,800 shares of DCPH stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,800
Previous 300 1500.0%
Holding current value
$0
Previous $4,000 1775.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$13.58 - $17.36 $2.05 Million - $2.62 Million
-150,738 Reduced 57.69%
110,550 $1.74 Million
Q4 2023

Feb 14, 2024

BUY
$10.11 - $16.54 $265,529 - $434,406
26,264 Added 11.18%
261,288 $4.21 Million
Q3 2023

Nov 14, 2023

BUY
$12.46 - $15.48 $2.93 Million - $3.64 Million
235,024 New
235,024 $2.99 Million
Q1 2023

May 15, 2023

BUY
$14.26 - $22.1 $693,962 - $1.08 Million
48,665 Added 49.89%
146,211 $2.26 Million
Q4 2022

Feb 14, 2023

SELL
$14.85 - $19.04 $1.53 Million - $1.96 Million
-103,098 Reduced 51.38%
97,546 $1.6 Million
Q3 2022

Nov 14, 2022

BUY
$12.38 - $20.23 $567,387 - $927,161
45,831 Added 29.6%
200,644 $3.71 Million
Q2 2022

Aug 15, 2022

SELL
$9.11 - $13.98 $220,744 - $338,749
-24,231 Reduced 13.53%
154,813 $2.04 Million
Q1 2022

May 16, 2022

BUY
$6.87 - $11.11 $1.02 Million - $1.64 Million
147,835 Added 473.69%
179,044 $1.66 Million
Q4 2021

Feb 14, 2022

SELL
$7.7 - $37.13 $211,118 - $1.02 Million
-27,418 Reduced 46.77%
31,209 $304,000
Q3 2021

Nov 15, 2021

SELL
$26.46 - $37.15 $2.79 Million - $3.91 Million
-105,334 Reduced 64.24%
58,627 $1.99 Million
Q2 2021

Aug 16, 2021

BUY
$32.73 - $47.95 $5.17 Million - $7.57 Million
157,956 Added 2630.41%
163,961 $6 Million
Q1 2021

May 17, 2021

SELL
$40.39 - $56.73 $932,281 - $1.31 Million
-23,082 Reduced 79.36%
6,005 $269,000
Q4 2020

Feb 16, 2021

SELL
$51.77 - $66.18 $6.86 Million - $8.76 Million
-132,414 Reduced 81.99%
29,087 $1.66 Million
Q3 2020

Nov 16, 2020

BUY
$43.8 - $58.16 $6.9 Million - $9.17 Million
157,616 Added 4057.04%
161,501 $8.29 Million
Q2 2020

Aug 14, 2020

SELL
$37.05 - $65.03 $15.7 Million - $27.5 Million
-422,492 Reduced 99.09%
3,885 $232,000
Q1 2020

May 15, 2020

BUY
$33.63 - $69.4 $13.9 Million - $28.7 Million
414,174 Added 3394.03%
426,377 $17.6 Million
Q4 2019

Feb 14, 2020

SELL
$31.7 - $69.93 $9.98 Million - $22 Million
-314,877 Reduced 96.27%
12,203 $760,000
Q3 2019

Nov 14, 2019

BUY
$19.95 - $38.85 $759,755 - $1.48 Million
38,083 Added 13.18%
327,080 $11.1 Million
Q2 2019

Aug 14, 2019

SELL
$21.05 - $26.21 $1.6 Million - $1.99 Million
-76,019 Reduced 20.83%
288,997 $6.52 Million
Q1 2019

May 15, 2019

SELL
$20.65 - $29.55 $3.56 Million - $5.1 Million
-172,427 Reduced 32.08%
365,016 $0
Q4 2018

Feb 14, 2019

BUY
$19.08 - $36.14 $4.24 Million - $8.02 Million
221,981 Added 70.37%
537,443 $11.3 Million
Q3 2018

Nov 13, 2018

BUY
$33.57 - $42.1 $9.67 Million - $12.1 Million
287,991 Added 1048.35%
315,462 $0
Q2 2018

Aug 10, 2018

BUY
$20.06 - $44.95 $22,748 - $50,973
1,134 Added 4.31%
27,471 $0
Q1 2018

May 11, 2018

BUY
$20.04 - $29.71 $527,793 - $782,472
26,337 New
26,337 $528,000
Q4 2017

Feb 09, 2018

SELL
$16.54 - $24.2 $4.32 Million - $6.33 Million
-261,436 Closed
0 $0
Q3 2017

Nov 09, 2017

BUY
$17.65 - $18.99 $4.61 Million - $4.96 Million
261,436
261,436 $4.97 Million

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.